ORYZON leads an Eurostars project to promote new epigenetic treatments
A consortium led by Oryzon Genomics has received once again the Eurostar qualification and funding approval by the Eureka Secretariat. In this case, the project aims to promote epigenetic treatments for oncology and neurodegenerative diseases. The consortium is formed by three of the most active SMEs in the field of epigenetics in Europe including the Spanish Oryzon.